论文部分内容阅读
胶质瘤是人类最常见的中枢神经系统原发性肿瘤,主要来自星形细胞,也可来自少突胶质细胞和室管膜细胞,尽管采用了包括外科手术、放疗、化疗和免疫疗法的综合治疗,但在过去20年中,胶质瘤患者的存活率几无提高。就恶性度最高的多形性成胶质细胞瘤而言,即使采用综合疗法,平均生存时间也只有11个月,几与30年前相同。疗效不佳的原因,除药物质量、手术彻底程度等因素外,胶质瘤细胞的低免疫原性、胶质瘤细胞的异质性、胶质瘤患者免疫功能低下等免疫生物学性质亦起着决定性作用。因此,要对胶质瘤的治疗手段作进一步的设想和改进,应考虑胶质瘤细胞的免疫生物学特性。
Gliomas are the most common primary tumors of the central nervous system in humans, mainly from astrocytes, but also from oligodendrocytes and ependymal cells, despite the use of a combination of surgery, radiotherapy, chemotherapy, and immunotherapy. Treatment, but in the past 20 years, the survival rate of glioma patients has not improved. With respect to the most aggressive form of glioblastoma multiforme, the average survival time is only 11 months, even when combined therapy is used, which is the same as 30 years ago. The reasons for poor efficacy, in addition to drug quality, thoroughness of surgery and other factors, the low immunogenicity of glioma cells, the heterogeneity of glioma cells, immune function of glioma patients and other immune biology Decisive role. Therefore, to further conceive and improve the treatment of gliomas, we should consider the immunobiological characteristics of glioma cells.